# Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

> **NCT00447226** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 32 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Oral lapatinib tablets or placebo tablets

## Key facts

- **NCT ID:** NCT00447226
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** 2009-05
- **Final completion:** 2009-09
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** The study had failed to meet the primary objective of tumor response rate at 12 weeks from first dose.
- **Last updated:** 2012-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00447226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00447226, "Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00447226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*